US Patent

US9034822 — Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2031-01-20 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of using antibodies as antidotes for dabigatran and related compounds during anticoagulant therapy.

USPTO Abstract

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1759 — dabigatran-etexilate-mesylate
U-1759 — dabigatran-etexilate-mesylate
U-1759 — dabigatran-etexilate-mesylate

Patent Metadata

Patent number
US9034822
Jurisdiction
US
Classification
Method of Use
Expires
2031-01-20
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.